sST2在心血管疾病中作用的研究进展

doi:10.3969/j.issn.1004-583X.2024.05.013

摘要/Abstract

摘要：

可溶性生长刺激表达基因2蛋白(soluble growth stimulation expressed gene 2, sST2)是一种细胞因子,已被证明可由心脏成纤维细胞、心肌细胞和血管内皮细胞中的生物力学应变诱导,与炎症反应和组织纤维化有关。近年来研究发现sST2与多种心血管疾病(cardiovascular disease,CVD)预后相关,可作为诊断CVD及评估预后的新型生物标志物。本文就sST2在CVD中的作用研究进展作一综述。

关键词: 心血管疾病, 可溶性生长刺激表达基因2蛋白, 诊断, 预后

中图分类号:

庞樱容, 孙欣. sST2在心血管疾病中作用的研究进展[J]. 临床荟萃, 2024, 39(5): 460-465.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2024.05.013

https://lchc.magtechjournal.com/CN/Y2024/V39/I5/460

参考文献 60

[1]	Homsak E, Gruson D. Soluble ST2: A complex and diverse role in several diseases[J]. Clin Chim Acta, 2020, 507: 75-87. doi: S0009-8981(20)30166-2 pmid: 32305537
[2]	Wang Y, Chen Z, Huang Y, et al. Prognostic significance of serum interleukins and soluble ST2 in Traditional Chinese Medicine (TCM) syndrome-differentiated rheumatoid arthritis[J]. Med Sci Monit., 2018, 24: 3472-3478.
[3]	Yu YZ, Gui XH, Yu M, et al. Soluble ST2 in serum predicts the prognosis of idiopathic pulmonary fibrosis: A retrospective study[J]. Ann Transl Med, 2022, 10(14): 797.
[4]	Saikumar Jayalatha AK, Hesse L, Ketelaar ME, et al. The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention[J]. Pharmacol Ther, 2021, 225: 107847.
[5]	Battista S, Bima P, Forno D, et al. Plasma soluble suppression of tumorigenesis 2 measured in the emergency department for diagnosis and outcome prediction of sepsis: A single-center prospective study[J]. Clin Chim Acta, 2024, 553: 117710.
[6]	Dudek M, Kałużna-Oleksy M, Migaj J, et al. Clinical value of soluble ST2 in cardiology[J]. Adv Clin Exp Med, 2020, 29(10): 1205-1210. doi: 10.17219/acem/126049 pmid: 33049127
[7]	Katsioupa M, Kourampi I, Oikonomou E, et al. Novel biomarkers and their role in the diagnosis and prognosis of acute coronary syndrome[J]. Life (Basel), 2023, 13(10): 1992.
[8]	Liu R, Liu L, Wei C, et al. IL-33/ST2 immunobiology in coronary artery disease: A systematic review and meta-analysis[J]. Front Cardiovasc Med, 2022, 9: 990007.
[9]	Zhang T, Xu C, Zhao R, et al. Diagnostic value of sST2 in cardiovascular diseases: A systematic review and meta-analysis[J]. Front Cardiovasc Med, 2021, 8: 697837.
[10]	Zhu Y, Pei L, Li N, et al. Preoperative sST2 levels relate to myocardial remodeling and cardiac function improvement after cardiac valve surgery[J]. ESC Heart Fail, 2024, 11(1): 91-98.
[11]	Witkowska A, Staciwa M, Duraj I, et al. Interleukin-33/sST2: Dynamic assessment in patients with acute coronary syndrome[J]. Adv Med Sci, 2023, 68(2): 195-201.
[12]	陈明, 张月兰. 血清可溶性生长刺激表达因子2水平与急性ST段抬高型心肌梗死患者冠状动脉病变程度及短期预后的相关性分析[J]. 中国医科大学学报, 2023, 52(7): 595-600.
[13]	Zhang J, Chen Z, Ma M, et al. Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance[J]. Front Cardiovasc Med, 2022, 9: 924461.
[14]	Aimo A, Migliorini P, Vergaro G, et al. The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?[J]. Int J Cardiol, 2018, 267: 188-192. doi: S0167-5273(18)30957-4 pmid: 29793758
[15]	Luo G, Qian Y, Sheng X, et al. Elevated serum levels of soluble ST2 are associated with plaque vulnerability in patients with non-st-elevation acute coronary syndrome[J]. Front Cardiovasc Med, 2021, 8: 688522.
[16]	Ip C, Luk KS, Yuen VLC, et al. Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis[J]. Int J Cardiol Heart Vasc, 2021, 37: 100887.
[17]	Liu L, Li S, Ding X, et al. Dynamic changes in soluble suppression of tumorigenicity 2 levels predict major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction[J]. Pol Arch Intern Med, 2022, 132(10): 16317.
[18]	Ji H, Yuan L, Jiang W, et al. Long-term prognostic importance of high levels of sST2 in patient with AMI: A meta-analysis[J]. Am J Transl Res, 2024, 16(1): 1-11. pmid: 38322566
[19]	Kercheva M, Ryabova T, Gusakova A, et al. Serum soluble ST2 and adverse left ventricular remodeling in patients with st-segment elevation myocardial infarction[J]. Clin Med Insights Cardiol, 2019, 13: 1179546819842804.
[20]	Mechtouff L, Paccalet A, Crola Da Silva C, et al. Prognosis value of serum soluble ST2 level in acute ischemic stroke and STEMI patients in the era of mechanical reperfusion therapy[J]. J Neurol, 2022, 269(5): 2641-2648.
[21]	Gerber Y, Weston SA, Enriquez-Sarano M, et al. Contemporary risk stratification after myocardial infarction in the community: Performance of scores and incremental value of soluble suppression of tumorigenicity-2[J]. J Am Heart Assoc, 2017, 6(10): e005958.
[22]	Kim M, Lee DI, Lee JH, et al. Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction[J]. Cardiol J, 2021, 28(2): 244-254.
[23]	Søndergaard FT, Beske RP, Frydland M, et al. Soluble ST2 in plasma is associated with post-procedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction[J]. Eur Heart J Acute Cardiovasc Care, 2023, 12(1): 48-52.
[24]	Zhang Q, Hu M, Ma S. Association of soluble suppression of tumorigenicity with no-reflow phenomenon and long-term prognosis in patients with non-st-segment elevation acute coronary syndrome after percutaneous coronary intervention[J]. J Atheroscler Thromb, 2021, 28(12): 1289-1297. doi: 10.5551/jat.59832 pmid: 33551392
[25]	Chen D, Untaru R, Stavropoulou G, et al. Elevated soluble suppressor of tumorigenicity 2 predict hospital admissions due to Major Adverse Cardiovascular Events (MACE)[J]. J Clin Med, 2023, 12(8): 2790.
[26]	Kim HL, Lee JP, Wong N, et al. Prognostic value of serum soluble ST2 in stable coronary artery disease: A prospective observational study[J]. Sci Rep, 2021, 11(1): 15203.
[27]	Alkhateeb A, Mahmoud HEM, Ak M, et al. Impact of myocardial ischemia and revascularization by percutaneous coronary intervention on circulating level of soluble ST2[J]. Vasc Health Risk Manag, 2023, 19: 411-420. doi: 10.2147/VHRM.S416206 pmid: 37434792
[28]	Lai J, Huang C, Li B, et al. Soluble ST2 as a possible biomarker for inflammation in patients with acute heart failure[J]. J Cardiovasc Med (Hagerstown), 2024, 25(3): 186-192. doi: 10.2459/JCM.0000000000001587 pmid: 38305120
[29]	Yang C, Fan Z, Wu J, et al. The diagnostic value of soluble ST2 in heart failure: A meta-analysis[J]. Front Cardiovasc Med, 2021, 8: 685904.
[30]	Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev, 2022, 27(2): 625-643.
[31]	Riccardi M, Myhre PL, Zelniker TA, et al. Soluble ST2 in heart failure: A clinical role beyond B-type natriuretic peptide[J]. J Cardiovasc Dev Dis, 2023, 10(11): 468.
[32]	Pascual-Figal DA, Pérez-Martínez MT, Asensio-Lopez MC, et al. Pulmonary production of soluble ST2 in heart failure[J]. Circ Heart Fail, 2018, 11(12): e005488.
[33]	van Vark LC, Lesman-Leegte I, Baart SJ, et al. Prognostic value of serial ST2 measurements in patients with acute heart failure[J]. J Am Coll Cardiol, 2017, 70(19): 2378-2388. doi: S0735-1097(17)39763-2 pmid: 29096809
[34]	Wang Z, Pan X, Xu H, et al. Serum soluble ST2 is a valuable prognostic biomarker in patients with acute heart failure[J]. Front Cardiovasc Med, 2022, 9: 812654.
[35]	Aimo A, Maisel AS, Castiglione V, et al. sST2 for outcome prediction in acute heart failure: Which is the best cutoff?[J]. J Am Coll Cardiol, 2019, 74(3): 478-479.
[36]	Aimo A, Januzzi Jr JL, Vergaro G, et al. Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T[J]. Eur J Heart Fail, 2020, 22(11): 2078-2088.
[37]	Emdin M, Aimo A, Vergaro G, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T[J]. J Am Coll Cardiol, 2018, 72(19): 2309-2320.
[38]	Dong G, Chen H, Zhang H, et al. Long-term and short-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in chronic heart failure: A systematic review and meta-analysis[J]. Cardiology, 2021, 146(4): 433-440.
[39]	Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America[J]. Circulation, 2017, 136(6): e137-e161.
[40]	Shi Y, Liu J, Liu C, et al. Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis[J]. Front Cardiovasc Med, 2022, 9: 937291.
[41]	Chen Y, Zhao X, Liang L, et al. sST2 and big ET-1 as alternatives of multi-biomarkers strategies for prognosis evaluation in patients hospitalized with heart failure[J]. Int J Gen Med, 2023, 16: 5003-5016. doi: 10.2147/IJGM.S435552 pmid: 37933253
[42]	Gao Y, Bai X, Lu J, et al. Prognostic value of multiple circulating biomarkers for 2-year death in acute heart failure with preserved ejection fraction[J]. Front Cardiovasc Med, 2021, 8: 779282.
[43]	Pérez-Sanz TM, Gómez-Salvador I, Codina P, et al. Soluble ST2, BCN-Bio-HF calculator and MAGGIC-HF score in long-term risk prediction after an urgent visit for heart failure[J]. Heart Vessels, 2024, 39(3): 216-225.
[44]	邢布点, 魏婷, 卢园园, 等. IL-33/sST2信号通路与原发性高血压左室肥厚患者的相关性研究[J]. 海南医学院学报, 2022, 28(21): 1621-1626.
[45]	Coglianese EE, Larson MG, Vasan RS, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham heart study[J]. Clin Chem, 2012, 58(12):1673-1681. doi: 10.1373/clinchem.2012.192153 pmid: 23065477
[46]	Wu F, Li L, Wen Q, et al. A functional variant in ST2 gene is associated with risk of hypertension via interfering MiR-202-3p[J]. J Cell Mol Med, 2017, 21(7): 1292-1299. doi: 10.1111/jcmm.13058 pmid: 28121058
[47]	Yin X, Cao H, Wei Y, et al. Alteration of the IL-33-sST2 pathway in hypertensive patients and a mouse model[J]. Hypertens Res, 2019, 42(11): 1664-1671. doi: 10.1038/s41440-019-0291-x pmid: 31235844
[48]	刘一炫, 蒙荣森, 廖禄明, 等. 原发性高血压患者血清标志物与心肌肥厚的相关性分析[J]. 中华老年心脑血管病杂志, 2023, 25(4): 368-372.
[49]	Wei P, Liu L, Wang X, et al. Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy[J]. ESC Heart Fail, 2022, 10(1): 303-310. doi: 10.1002/ehf2.14147 pmid: 36210061
[50]	Farcaᶊ AD, Mocan M, Anton FP, et al. Short-term prognosis value of sST2 for an unfavorable outcome in hypertensive patients[J]. Dis Markers, 2020, 2020: 8143737.
[51]	Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5): 373-498. doi: 10.1093/eurheartj/ehaa612 pmid: 32860505
[52]	武锋超, 蓝庆肃, 马兰虎, 等. 可溶性ST2与心房颤动的研究进展[J]. 岭南心血管病杂志, 2021, 27(5): 608-610+614.
[53]	Liu JH, Han QF, Mo DG. The progress of the soluble suppression of tumorigenicity 2 (sST2) in atrial fibrillation[J]. J Interv Card Electrophysiol, 2022, 65(3): 591-592.
[54]	Sun WP, Du X, Chen JJ. Biomarkers for predicting the occurrence and progression of atrial fibrillation: Soluble suppression of tumorigenicity 2 protein and tissue inhibitor of matrix metalloproteinase-1[J]. Int J Clin Pract, 2022, 2022: 6926510.
[55]	Yan X, Guo Y, Li L, et al. The sST2 level is an independent influencing factor associated with atrial fibrillation in heart failure patients: A case-control study[J]. J Thorac Dis, 2022, 14(5): 1578-1587. doi: 10.21037/jtd-22-470 pmid: 35693622
[56]	Chen L, Chen W, Shao Y, et al. Association of soluble suppression of tumorigenicity 2 with new-onset atrial fibrillation in acute myocardial infarction[J]. Cardiology, 2022, 147(4): 381-388. doi: 10.1159/000524765 pmid: 35580569
[57]	Fan J, Li Y, Yan Q, et al. Higher serum sST2 is associated with increased left atrial low-voltage areas and atrial fibrillation recurrence in patients undergoing radiofrequency ablation[J]. J Interv Card Electrophysiol, 2022, 64(3): 733-742.
[58]	Tan R, Yu H, Han X, et al. Circulating soluble suppression of tumorigenicity 2 predicts recurrence after radiofrequency ablation of persistent atrial fibrillation[J]. Front Cardiovasc Med, 2021, 8: 653312.
[59]	Tan ESJ, Chan SP, Liew OW, et al. Atrial fibrillation and the prognostic performance of biomarkers in heart failure[J]. Clin Chem, 2021, 67(1): 216-226. doi: 10.1093/clinchem/hvaa287 pmid: 33279970
[60]	李明瑞, 钟志雄. 血清可溶性ST2在心力衰竭中的研究进展[J]. 海南医学, 2022, 33(15): 2004-2007.

sST2在心血管疾病中作用的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 60

相关文章 15

编辑推荐

Metrics

本文评价

[1]	蒲武涛, 肖宜欣, 妥丽, 凯丽比努尔·马木提, 范雪婷, 崇乐. 超声造影诊断肝包虫病的系统评价和meta分析[J]. 临床荟萃, 2025, 40(3): 197-204.
[2]	李忠标, 赵习浩, 杜敏, 王江, 于跃, 张佃良. 肠腔内生性卵巢外腹膜浆液性乳头状腺癌1例并文献复习[J]. 临床荟萃, 2025, 40(3): 257-261.
[3]	季万里, 马周, 石郁喜, 孙为生. 青年脊髓硬脊膜动静脉瘘1例并文献复习[J]. 临床荟萃, 2025, 40(3): 262-265.
[4]	陈诚, 钱卓宇, 全栩毅, 段圣武. 结直肠癌浆膜及肌层受累影像诊断的研究进展[J]. 临床荟萃, 2025, 40(3): 281-284.
[5]	叶倩, 刘申香. D-二聚体与接受PD-1/PD-L1抑制剂治疗的晚期肿瘤患者长期预后的关系:一项Meta分析[J]. 临床荟萃, 2025, 40(2): 101-106.
[6]	申帅洁, 陈荣梯, 朱嵩, 平芬. 乳酸脱氢酶在难治性肺炎支原体肺炎中的临床应用进展[J]. 临床荟萃, 2025, 40(2): 185-188.
[7]	张雪, 王俊祥. 类风湿关节炎共病的研究进展[J]. 临床荟萃, 2025, 40(1): 86-89.
[8]	张迎秋, 张津, 葛世豪, 陈俊敏. 成人DWI脑皮质“花边征”1例并文献复习[J]. 临床荟萃, 2024, 39(9): 821-824.
[9]	散丹, 甄瑾. 脊髓硬脊膜动静脉瘘1例并文献复习[J]. 临床荟萃, 2024, 39(9): 825-827.
[10]	张中楼, 崔坤, 孟晋启. 运动保护心血管系统的研究进展[J]. 临床荟萃, 2024, 39(9): 855-860.
[11]	马剑楠, 陶杰, 桑大森, 吴寿岭, 张旗. 尿转铁蛋白与2型糖尿病人群新发心血管疾病的关系[J]. 临床荟萃, 2024, 39(8): 700-705.
[12]	郝苑苑, 王君, 黄茜. 经直肠超声联合超声造影对前列腺低回声病灶良恶性诊断的价值[J]. 临床荟萃, 2024, 39(7): 635-639.
[13]	申彤彤, 匡竞, 王玮. 血清肿瘤标志物在肝细胞癌早期诊断中的应用[J]. 临床荟萃, 2024, 39(6): 563-567.
[14]	王茜, 尹万红, 邹同娟, 铁馨, 朱俊臣, 陈侣林, 曾学英. 机械通气脓毒症患者肺部超声重力依赖失充气表型与不良预后的相关性[J]. 临床荟萃, 2024, 39(4): 314-319.
[15]	宋梦姣, 王睿琪, 曹灿, 程光森, 刘羽, 李忠亮, 杨建豪. 血尿酸与首次急性缺血性脑卒中患者TOAST分型及预后的相关性[J]. 临床荟萃, 2024, 39(3): 216-221.